Vumerity (diroximel fumarate) approved for relapsing remitting MS in England and Wales

12 April 2022

The MS Trust is delighted that Vumerity (diroximel fumarate) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis.

NICE has recommended that Vumerity can be prescribed for people with relapsing remitting MS who are having relapses or have MRI evidence of MS activity.

This is excellent news. Vumerity is as effective as Tecfidera but has fewer stomach problems, meaning you can take it with a meal or on an empty stomach. An effective treatment that fits into your daily routines means you can live a life with MS that is not defined by MS.

- David Martin, Chief Executive Officer, MS Trust

The Scottish Medicines Consortium approved Vumerity in February this year. In Northern Ireland, the Department of Health reviews and endorses appropriate NICE appraisals.

About Vumerity

Vumerity (diroximel fumarate) is taken as a tablet, twice daily. You start with a low dose for the first week then increase to the full dose. This gives your body time to get used to the new treatment, reducing the risk of side effects.

Vumerity is similar to Tecfidera. In the body, both drugs are converted to monomethyl fumarate which reduces inflammation caused by MS activity and may protect nerve cells from damage.

In clinical trials, Vumerity reduced relapse rates and the number of active lesions seen on MRI scans.

The most common side effects reported in clinical trials were gastrointestinal discomfort and flushing. People taking Vumerity experienced fewer days of gastrointestinal symptoms, took less medication for gastrointestinal symptoms and missed less work compared to Tecfidera. Participants who stopped treatment because of gastrointestinal problems was 0.8% for Vumerity and 4.8% for Tecfidera.

Other side effects included nasopharyngitis (common cold), diarrhoea and chest infections.

Find out more